GRAY News and Press, Graybug Vision Inc. From 06/28/22

We’re in the final stretch of June 2022 and the last few days of the second quarter. Gross Domestic Product results for the quarter and additional CPI data are also due out before July. Whether they reveal a recession, higher inflation, or something completely different may not matte...

Graybug Vision (NASDAQ:GRAY) stock soared 65% on June 28 after the company said its board will undertake a review of strategic alternatives, including potential sale or merger transactions. Graybug said it will explore the potential for an acquisition, company sale or of assets, merger, priva...

BALTIMORE, June 28, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that its Board of Directors will conduct a comprehensive review o...

BALTIMORE, May 19, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that Parisa Zamiri, MD, PhD, Chief Medical Officer of Graybug Visi...

Graybug Vision press release (NASDAQ:GRAY): Q1 GAAP EPS of -$0.48. As of March 31, 2022, the company’s cash, cash equivalents, and short-term investments totaled $55.3 million, compared to $63.7 million as of December 31, 2021. For further details see: Graybug Vision GAAP EPS of ...

BALTIMORE, May 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today provided an update on recent corporate developments and anticipated milestones, and reported ...

The following slide deck was published by Graybug Vision, Inc. in conjunction with this event. For further details see: Graybug Vision (GRAY) Presents at The ASCRS Annual Meeting - Slideshow

BALTIMORE, April 27, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a poster presentation of preclinical data for GB-401 in primary ...

BALTIMORE, April 18, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a platform presentation at the upcoming American Society of Cata...

BALTIMORE, April 13, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced the appointment of Dirk Sauer, PhD, to the Graybug Board of Dire...